Mark Woodward, 4 Phillipe Amouyel, 3 Gordon D.O. Lowe, 5 C-reactive protein (CRP), the classic marker of acutephase response, is an indicator of a variety of pathologic processes, including infections, tissue damage, and chronic inflammatory diseases (1, 2 ) . The majority of more than 15 well-conducted prospective studies in initially healthy individuals have shown a strong and independent association between concentrations of CRP within the reference interval (Ͻ5 mg/L) and future major cardiovascular events (3 ), although in some of them, no such association could be established (4 -7 ) . The summary estimate of the relative risk in formal metaanalysis was 2.0 (95% confidence interval, 1.6 -2.5) (3 ). Furthermore, CRP has been shown to add to risk prediction beyond and above established cardiovascular risk factors (8 ) . On the basis of data from the Physicians' Health Study and the Nurses' Health Study, an algorithm for risk assessment of future coronary events that combines both CRP concentration and the ratio of total cholesterol to HDL-cholesterol has recently been proposed (9 ) .
Because atherosclerosis represents a low-grade inflammatory process in the vascular bed, high-sensitivity (hs) assays are needed when using circulating CRP concentrations for risk prediction in cardiovascular diseases. Such assays have been developed and are now commercially available (10, 11 ) . However, before screening of individuals at risk can be recommended, CRP distributions in apparently healthy adults in the general population must be known. Such information is scarce. Furthermore, in previous reports, women using oral contraceptives or receiving hormone replacement therapy (HRT), both of Clinical Chemistry 49, No. 4, 2003 which have been shown to significantly increase CRP concentrations, had not been excluded (12) (13) (14) (15) . In this report, we describe the frequency distribution of CRP concentrations in 13 527 adult men and women from different representative populations in Western Europe. (10, 16, 17 ) . All serum/plasma samples were immediately stored after collection and frozen at Ϫ70 to Ϫ90°C until analysis.
CRP was determined in these populations by two different methods. A sensitive solid-phase monoclonalpolyclonal IRMA with a range of 0.05-10.0 mg/L was used for all samples except for the MONICA/KORA Augsburg survey 1999 -2000 and for the Glasgow MONICA survey 1992. Method details have been described elsewhere (10 ) . The intraassay CVs ranged from 5.6% for the 0.50 mg/L calibrator to 1.4% for the 0.10 mg/L calibrator; the interassay CVs ranged between 8.0% for the 0.5 mg/L calibrator and 0.5% for the 0.10 mg/L calibrator. All samples with values exceeding the upper limit of the assay range, i.e., 10 mg/L, were reassayed at appropriately higher sample dilutions. CRP concentrations in the MONICA/KORA Augsburg sample 1999 -2000 and in the Glasgow MONICA sample 1992 were measured by a particle-enhanced immunonephelometric assay performed on a BN II Analyzer (Dade Behring) (11 ) . The interassay CVs were Ͻ6% for both samples. There was no difference in CRP measurements between serum and plasma samples. Validation analyses between the two methods have been performed in a sample of 792 men and women from a case-control study (18 ) . Comparisons according to Bland and Altman (19 ) after log-transformation of CRP concentrations gave a mean difference between the IRMA and the BN II of Ϫ0.11 with 95% limits of agreement of Ϫ1.17 and 0.95, indicating excellent agreement between the two methods. The Spearman rank correlation coefficient was 0.87 (unpublished data).
In all samples, CRP concentrations were highly skewed to the right among both men and women. There was a trend to higher CRP values with increasing age in all samples. Median CRP values for men and women, the latter not taking oral contraceptives or HRT, up to 44 years of age were 0.6 -1.1 mg/L among the seven samples, and among those 45 years of age and older, the median CRP values were 1.2-1.7 mg/L ( Table 1) . Slight differences between CRP medians in the samples could mainly be explained by the somewhat different age ranges covered, above and below the cutpoints of 45 years. Distributions of CRP were comparable between men and women among the different geographic areas studied and were stable over time in the MONICA Augsburg samples (men 45 years and above, 1.6 -1.7 mg/L). Fewer than 5% of men and women had CRP Ͼ10 mg/L, indicating an ongoing high-grade inflammatory process, such as acute infection. However, a remarkable subsample of up to one-third of individuals had CRP concentrations Ͼ3 mg/L, which has been shown in several studies to be associated with an increased risk for future cardiovascular events (20 ) .
We have described frequency distributions of hs-CRP in seven cross-sectional samples randomly selected from the adult general population of three European countries (Germany, France, and Scotland). Data sets included both genders, excluded women on oral contraceptives or HRT, and covered a wide age range. Furthermore, we looked for potential changes of CRP over time in the MONICA Augsburg samples covering a time period of ϳ15 years. In all samples, CRP distributions were highly skewed to the right, increased with age, and were similar in adult men and in women who neither used oral contraceptives nor received HRT. In addition, CRP concentrations in the general population did not substantially differ among the geographic areas studied and were stable over time.
On the basis of the risk prediction for cardiovascular endpoints associated with increased CRP (3, 21, 22 ) , measuring this biomarker has recently been suggested as an additional tool for risk stratification (9 ) . However, a new risk marker of disease needs to fulfill several requirements (23 ) . It should show high sensitivity and specificity and low intraindividual variability but high interindividual variation. For CRP, sensitive and robust methods are commercially available (11 ) . However, although CRP represents an extremely sensitive marker of the acutephase response, it is completely unspecific and is influenced by a variety of disease states, including infections, rheumatic diseases, and malignancies among others (24 ) .
Frequency distributions of a marker designated for risk assessment in the general population are inevitably required for identifying individuals at increased risk. For CRP, such reports are scarce, and, to the best of our knowledge, no data from European countries exist from which women on oral contraceptives or HRT have been excluded. Median CRP concentrations in these samples are comparable to those reported from other populations (25, 26 ) . Furthermore, CRP distributions among men and women not receiving hormones are very similar; thus, sex-specific cutpoints for risk stratification are not needed. Moreover, CRP concentrations in regions from three European countries with different social status and lifestyle habits are remarkably consistent.
The present analysis has several limitations. Only single measurements were performed, which may not reflect the true long-term values for the respective individuals; and we studied only Caucasians. We did not exclude individuals with diseases that might have affected CRP concentrations because this would have led to a selection bias that could have affected the generalizability of our results. However, the numbers of such persons were small in all of the samples. Serum/plasma samples from all participants had been stored immediately after collection at Ϫ70 to Ϫ90°C for up to 12 years. CRP is known to be a very stable protein, and in one study (27 ) , no significant change was seen in CRP concentrations of samples stored at 4°C for 5 months and at Ϫ20°C for up to 25 months.
Our own data from measurements of pooled samples over a period of 5 years also showed no systematic shift (unpublished data). Our analyses also have several strengths. The two hs-CRP assays that we used showed excellent agreement and were standardized according to the WHO reference standard (85/506) (28 ) . Finally, the examined populations were representative of the general population in three Western European countries.
Unsolved issues remain relating to the fact that, despite similarities in its distribution, CRP has been shown to be predictive for future cardiovascular events in various populations with greatly differing absolute risks (3, 29, 30 ) . In addition, CRP distributions are comparable between men and women, but cardiovascular risk is clearly different between them. Finally, CRP concentrations were stable over time although, e.g., data from the MONICA project indicate a decrease in coronary heart disease morbidity and mortality in several centers during a 10-year period.
In summary, our data describing CRP concentrations in representative populations may be useful for the clinician and the general practitioner in assessing the risk of future cardiovascular events by means of hs-CRP. 
